GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
- First Posted Date
- 2019-10-15
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 464
- Registration Number
- NCT04126200
- Locations
- 🇸🇪
GSK Investigational Site, Stockholm, Sweden
Study of Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline's (GSK)Respiratory Syncytial Virus (RSV)Maternal Unadjuvanted Vaccine in Healthy Pregnant Women (Aged 18 to 40 Years) and Their Infants
- Conditions
- Interventions
- First Posted Date
- 2019-10-15
- Last Posted Date
- 2021-12-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 534
- Registration Number
- NCT04126213
- Locations
- 🇪🇸
GSK Investigational Site, Marbella, Spain
A Phase 3 Clinical Study Investigating the Gingivitis Efficacy of a Test Dentifrice Containing Stannous Fluoride
- Conditions
- Interventions
- First Posted Date
- 2019-10-11
- Last Posted Date
- 2020-01-31
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 98
- Registration Number
- NCT04123665
- Locations
- 🇺🇸
GSK Investigational Site, Fort Wayne, Indiana, United States
Effects of Intravenous GSK3858279 on a Battery of Evoked Pain Tests in Healthy Volunteers
- First Posted Date
- 2019-10-03
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 21
- Registration Number
- NCT04114656
- Locations
- 🇳🇱
GSK Investigational Site, Leiden, Netherlands
Relative Bioavailability Study of Marketed and Lower Dose Ambrisentan in Healthy Adult Participants
- Conditions
- Interventions
- First Posted Date
- 2019-09-19
- Last Posted Date
- 2020-08-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 29
- Registration Number
- NCT04095286
- Locations
- 🇬🇧
GSK Investigational Site, Cambridge, Cambridgeshire, United Kingdom
Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2019-09-16
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 144
- Registration Number
- NCT04091126
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) Who Had Prior Episode of Shingles
- Conditions
- Interventions
- First Posted Date
- 2019-09-16
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1426
- Registration Number
- NCT04091451
- Locations
- 🇬🇧
GSK Investigational Site, Nantwich, Cheshire, United Kingdom
A Study to Test GlaxoSmithKline's (GSK) Respiratory Syncytial Virus RSV Candidate Vaccine's Safety and Immune Response in Japanese Older Adults
- Conditions
- Interventions
- First Posted Date
- 2019-09-16
- Last Posted Date
- 2022-02-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 40
- Registration Number
- NCT04090658
- Locations
- 🇯🇵
GSK Investigational Site, Fukuoka, Japan
Pharmacokinetics of Gepotidacin Tablets in Adults and Adolescents Subjects
- First Posted Date
- 2019-09-06
- Last Posted Date
- 2020-09-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 34
- Registration Number
- NCT04079790
- Locations
- 🇺🇸
GSK Investigational Site, Las Vegas, Nevada, United States
A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Experimental Rabies Vaccine in Healthy Adults
- Conditions
- Interventions
- Biological: Lower dose formulation of RG SAM (CNE) vaccine (GSK3903133A)Biological: Medium dose formulation of RG SAM (CNE) vaccine (GSK3903133A)Biological: Low dose formulation of RG SAM (CNE) vaccine (GSK3903133A)Biological: Lowest dose formulation of RG SAM (CNE) vaccine (GSK3903133A)Drug: Saline PlaceboBiological: RabAvert
- First Posted Date
- 2019-08-20
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 160
- Registration Number
- NCT04062669
- Locations
- 🇺🇸
GSK Investigational Site, Rochester, New York, United States